← Leaderboards
Thomas Horn
Iit Research Institute
$2,256,553
Attributed
$2,256,553
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,256,553 · 3
By mechanism
N01$2,256,553 · 3
Top collaborators
No co-investigators on record.
Most similar at Iit Research Institute
Same institution · by research overlap
- David McCormick$23,114,492
- Michael O'Ryan$1,031,549
- David L. McCormick$9,946,066
- Ph.d., D.a.b.t., David McCormick$2,861,154
- Ph.d. Dabt, David McCormick$2,029,696
Others in their field
Other Emerging Leaders on “Toxic Effect”
- Matthew Johnson · Duke University$56,071,536
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,853,758
- Kristin Aillon · Midwest Research Institute$24,228,962
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Xinhua Li · Nano Terra, Inc.$17,491,533
- Thomas Denny · Duke University$16,626,143
Research focus
Toxic EffectAgonistRecoveryToxicokineticsRattusSubcutaneousSafetyMetaphyseal ChondrodysplasiaNational Institute Of Neurological Disorders And StrokeOralAcuteOverdosePharmacology And ToxicologyProgramsSafety AssessmentSmall MoleculeSolidOrganCanis FamiliarisCannabinoid Receptor AntagonistCannabinoidsContractsImmunologicsMalignant Neoplasms
Grant awards (5)
FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS$512,266
N01 · FY2024 · DA · contact PI
NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.$115,334
N01 · FY2024 · DA · contact PI
NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO)$1,425,732
N01 · FY2023 · DA · contact PI
NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.$201,709
N01 · FY2023 · DA · contact PI
CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP)$1,512
N01 · FY2021 · DA · contact PI